Boceprevir

Janessa Smith, Pharm.D. BCPS, Paul A. Pham, PharmD
Boceprevir is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Boceprevir is indicated for the treatment of HCV (genotype1, used in combination with peg-INF + ribavirin) in adult patients with compensated liver disease, including cirrhosis.
    • Boceprevir may be used in either treatment-naïve patients or those who have failed previously interferon/ribavirin therapy.

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

  • Boceprevir is indicated for the treatment of HCV (genotype1, used in combination with peg-INF + ribavirin) in adult patients with compensated liver disease, including cirrhosis.
    • Boceprevir may be used in either treatment-naïve patients or those who have failed previously interferon/ribavirin therapy.

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: March 4, 2018